FI3345604T3 - Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa - Google Patents

Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa Download PDF

Info

Publication number
FI3345604T3
FI3345604T3 FIEP17206034.5T FI17206034T FI3345604T3 FI 3345604 T3 FI3345604 T3 FI 3345604T3 FI 17206034 T FI17206034 T FI 17206034T FI 3345604 T3 FI3345604 T3 FI 3345604T3
Authority
FI
Finland
Prior art keywords
nalmefene
use according
alcohol
patient
day
Prior art date
Application number
FIEP17206034.5T
Other languages
English (en)
Finnish (fi)
Inventor
Lars Torup
Afsaneh Abbariki
Anna Bladström
Christine Persson
Didier Meulien
Per Sørensen
Thomas Jensen
Jette Østergaard
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3345604(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of FI3345604T3 publication Critical patent/FI3345604T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
FIEP17206034.5T 2012-06-27 2013-06-27 Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa FI3345604T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
FI3345604T3 true FI3345604T3 (fi) 2023-07-28

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17206034.5T FI3345604T3 (fi) 2012-06-27 2013-06-27 Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP4223296B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK3345604T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES3014068T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20161717T1 (enExample)
HU (4) HUE070621T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT3138564T (enExample)
ME (2) ME03030B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL3138564T3 (enExample)
PT (3) PT2866808T (enExample)
RS (2) RS57046B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI2866808T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
SG11201608766TA (en) 2014-04-22 2016-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
EA019331B1 (ru) 2009-05-25 2014-02-28 Х. Лундбекк А/С Получение налмефена гидрохлорида из налтрексона
RS55777B1 (sr) 2010-11-05 2017-07-31 H Lundbeck As Postupak za proizvodnju naltreksona
JP5738470B2 (ja) 2011-03-31 2015-06-24 イムネクス ファーマ イラチュ サナイ ヴェ ティジャレット ア.シェ.Imuneks Farma Ilac Sanayi Ve Ticaret A.S. オピオイド拮抗体組成物、および強皮症の治療のためのその使用
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
EP4223296A3 (en) 2023-09-27
EP4223296A2 (en) 2023-08-09
SMT201600471T1 (it) 2017-03-08
KR20150023396A (ko) 2015-03-05
LT3138564T (lt) 2018-04-10
BR112014032555A2 (pt) 2017-06-27
SG11201408704WA (en) 2015-01-29
SI3138564T1 (en) 2018-04-30
AU2013283281B2 (en) 2017-04-20
ME02587B (me) 2017-06-20
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
HRP20230762T8 (hr) 2024-01-05
EP4223296B1 (en) 2025-01-29
SMT201800164T1 (it) 2018-07-17
CO7160087A2 (es) 2015-01-15
CA2874703C (en) 2022-08-23
DK2866808T3 (en) 2017-01-16
HK1208185A1 (en) 2016-02-26
HRP20180363T1 (hr) 2018-04-20
DK3345604T3 (da) 2023-07-24
EP4541421A3 (en) 2025-06-18
US10034874B2 (en) 2018-07-31
JP6857684B2 (ja) 2021-04-14
EP3345604B1 (en) 2023-06-07
JP2015521647A (ja) 2015-07-30
LT3345604T (lt) 2023-08-10
RU2014151156A (ru) 2016-08-20
RS55456B1 (sr) 2017-04-28
JP2018039810A (ja) 2018-03-15
PT3345604T (pt) 2023-07-17
LT2866808T (lt) 2017-01-10
MX371373B (es) 2020-01-28
EP4223296C0 (en) 2025-01-29
PT2866808T (pt) 2017-01-03
US9642849B2 (en) 2017-05-09
HRP20230762T1 (hr) 2023-10-13
RS57046B1 (sr) 2018-05-31
HRP20250329T1 (hr) 2025-05-09
MX2014015488A (es) 2015-03-06
HUE070621T2 (hu) 2025-06-28
DK3138564T3 (en) 2018-03-26
JP2019163275A (ja) 2019-09-26
US20140005217A1 (en) 2014-01-02
HRP20161717T1 (hr) 2017-02-10
EP3345604A1 (en) 2018-07-11
SI3345604T1 (sl) 2023-08-31
CA2874703A1 (en) 2014-01-03
JP6258933B2 (ja) 2018-01-10
CY1118579T1 (el) 2017-07-12
EP4541421A2 (en) 2025-04-23
ES2663532T3 (es) 2018-04-13
EP3138564B1 (en) 2018-01-31
US20180028526A1 (en) 2018-02-01
EA201492152A1 (ru) 2015-11-30
IL236035A0 (en) 2015-01-29
HK1255683A1 (en) 2019-08-23
PL2866808T3 (pl) 2017-04-28
PL3138564T3 (pl) 2018-06-29
HUE063313T2 (hu) 2024-01-28
HUE031110T2 (en) 2017-06-28
EP2866808A1 (en) 2015-05-06
CL2014003484A1 (es) 2015-02-27
MY166914A (en) 2018-07-24
PT3138564T (pt) 2018-04-03
PL3345604T3 (pl) 2023-08-28
EP3138564A1 (en) 2017-03-08
PL4223296T3 (pl) 2025-04-14
WO2014001427A1 (en) 2014-01-03
UA114199C2 (uk) 2017-05-10
ZA201409525B (en) 2016-08-31
IL236035B (en) 2018-12-31
ES2609122T3 (es) 2017-04-18
CY1120097T1 (el) 2018-12-12
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
SMT201600471B (it) 2017-03-08
AU2013283281A1 (en) 2014-12-11
ME03030B (me) 2018-10-20
ES3014068T3 (en) 2025-04-16
US20140005216A1 (en) 2014-01-02
EP2866808B1 (en) 2016-11-02
CN104411313A (zh) 2015-03-11
HUE036272T2 (hu) 2018-06-28
NZ702191A (en) 2017-06-30
EA029908B1 (ru) 2018-05-31
ES2950492T3 (es) 2023-10-10
CY1126140T1 (el) 2023-11-15

Similar Documents

Publication Publication Date Title
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX385798B (es) Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados.
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
WO2012079092A3 (en) Testosterone undecanoate compositions
NZ596879A (en) Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
MY194947A (en) Intranasal pharmaceutical dosage forms comprising naloxone
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
FI3345604T3 (fi) Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP2014516942A5 (enExample)
JP2009280621A5 (enExample)
MX2009003518A (es) Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
HRP20171678T1 (hr) Postupci za smanjenje prejedanja ili kompulzivnog jedenja
JP2018039810A5 (enExample)
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
IN2014MN02156A (enExample)
JP2012041314A5 (enExample)
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
NZ602032A (en) Oral b12 therapy
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.
RU2012114097A (ru) Терапевтический агент против хронической боли
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease